Associate Professor Jingjie Zhao: Standardized Design and Implementation Using Recognized Endpoint Indicators to Provide High-Quality Evaluation for TCM Intervention in Metabolic-Associated Fatty Liver Disease Research

Associate Professor Jingjie Zhao: Standardized Design and Implementation Using Recognized Endpoint Indicators to Provide High-Quality Evaluation for TCM Intervention in Metabolic-Associated Fatty Liver Disease Research

On May 18, 2024, the "25th National Academic Conference on Traditional Chinese Medicine for Hepatobiliary Diseases" was successfully held in Chongqing. The conference invited masters of Chinese medicine, academicians, nationally renowned TCM doctors, and leading experts in hepatology from both traditional Chinese and Western medicine to present academic reports. The focus was on hot and challenging issues in TCM hepatology, showcasing the latest achievements in TCM treatment of liver diseases. At the conference, Associate Professor Jingjie Zhao from the TCM Department of Beijing Friendship Hospital, Capital Medical University, delivered a brilliant report titled "Quality Evaluation of Randomized Controlled Clinical Trials on TCM Intervention in Non-Alcoholic Fatty Liver Disease." The following is a summary of her report for our readers.
Chairman Interview丨Professor Chunjun Xu: A Holistic Approach to the Treatment of Primary Liver Cancer

Chairman Interview丨Professor Chunjun Xu: A Holistic Approach to the Treatment of Primary Liver Cancer

Primary liver cancer is currently the 4th most common malignant tumor and the 2nd leading cause of cancer-related death in China, posing a serious threat to the life and health of the Chinese people. Traditional Chinese Medicine (TCM) has extensive clinical experience in treating primary liver cancer, using a syndrome differentiation approach at different stages of the disease based on its etiology and pathogenesis. At the recent "25th National Academic Conference on Traditional Chinese Medicine for Hepatobiliary Diseases" organized by the Hepatobiliary Disease Branch of the Chinese Association of Traditional Chinese Medicine, Professor Chunjun Xu, chairman of the Hepatobiliary Disease Branch, gave an exclusive interview with Hepatology Digest to discuss the treatment of primary liver cancer with TCM. Here is a compiled version of the interview for our readers.
Machine Learning Prognostic Model for Epstein-Barr Virus Reactivation after Haploidentical Hematopoietic Stem Cell Transplantation

Machine Learning Prognostic Model for Epstein-Barr Virus Reactivation after Haploidentical Hematopoietic Stem Cell Transplantation

In January 2023, a  study led by Professor Xiao Jun Huang from Peking University People's Hospital was published in the international academic journal ——Blood Science . The title of the study is "Machine learning algorithm as a prognostic tool for Epstein-Barr virus reactivation after haploidentical hematopoietic stem cell transplantation". This study elucidates the machine learning algorithm-based model for predicting EBV reactivation after haploidentical HSCT demonstrates not only promising results but also a transformative potential for personalized post-transplant care.
Micheliolide exerts effects in myeloproliferative neoplasms through inhibiting STAT3/5 phosphorylation via covalent binding to STAT3/5 proteins

Micheliolide exerts effects in myeloproliferative neoplasms through inhibiting STAT3/5 phosphorylation via covalent binding to STAT3/5 proteins

In July 2023, a study led by Professor Zhijian Xiao from Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College was published in the international academic journal ——Blood Science . The title of the study is "Micheliolide exerts effects in myeloproliferative neoplasms through inhibiting STAT3/5 phosphorylation via covalent binding to STAT3/5 proteins". This study elucidates micheliolide (MCL) is a promising drug in combination with ruxolitinib for the treatment of MPNs.
EBMT Exclusive Interview | Professor Yanmin Zhao: Maintenance Treatment Strategies for FLT3-ITD Mutant AML Patients After Transplantation

EBMT Exclusive Interview | Professor Yanmin Zhao: Maintenance Treatment Strategies for FLT3-ITD Mutant AML Patients After Transplantation

FMS-like tyrosine kinase 3 (FLT3) mutations, particularly internal tandem duplication mutations (FLT3-ITD), are one of the significant factors affecting the prognosis of patients with acute myeloid leukemia (AML). Overcoming the challenge of relapse after transplantation in patients with FLT3-mutated AML remains a significant clinical hurdle. At the 50th European Bone Marrow Transplantation (EBMT) annual meeting, Professor Yanmin Zhao from The First Affiliated Hospital of Zhejiang University School of Medicine presented a study (Abstract No.: OS18-08), which explored the impact of mutations in myelodysplasia-related (MR) genes on maintenance treatment outcomes after transplantation for FLT3-ITD AML patients. "Oncology Frontier - Hematology Frontier" invited Professor Yanmin Zhao to share insights into the maintenance treatment strategies, challenges, and future research directions for FLT3-ITD mutant AML patients after transplantation.
Digital Management of Chronic Progressive Liver Disease in China: Monthly Literature Review (April 2024, Issue 80)

Digital Management of Chronic Progressive Liver Disease in China: Monthly Literature Review (April 2024, Issue 80)

Hello, esteemed experts and colleagues. In this issue of the CDM Monthly Review (Issue 80), we will share six recent articles on the diagnosis and treatment of portal hypertension (four on diagnosis and monitoring, and two on multidisciplinary treatment). We have invited the following experts to review this month's issue: Dr. Yifei Huang from the Department of Gastroenterology at the Third Affiliated Hospital,Sun Yat-sen University, Professor Yali Xiong from the Department of Infectious Diseases at Nanjing Drum Tower Hospital, and Dr. Jiacheng Liu from the Department of Interventional Radiology at Union Hospital, Tongji Medical College, Huazhong University of Science and Technology.
Professor Shichun Lu’s Team: Proportion of Viable Tumor Cells Predicts Prognosis of Targeted Immunotherapy for Liver Cancer

Professor Shichun Lu’s Team: Proportion of Viable Tumor Cells Predicts Prognosis of Targeted Immunotherapy for Liver Cancer

Recently, Professor Shichun Lu's team from the Chinese PLA General Hospital published an article titled "Application of Proportion of Viable Tumor Cells in Prognosis Evaluation of Initial Unresectable Hepatocellular Carcinoma Patients Undergoing Sequential Surgical Treatment After Conversion Therapy" in the professional journal Chinese Journal of Hepatobiliary Surgery. The study retrospectively analyzed clinical data and pathological evaluations of 80 initially unresectable HCC patients who received PD-1 antibody combined with tyrosine kinase inhibitors (TKIs) as conversion therapy followed by sequential surgical treatment. The research team confirmed the value of the proportion of viable tumor cells (RVTCs) in surgical pathology specimens as a prognostic marker for patients undergoing conversion surgery and identified the optimal threshold for RVTCs (15%) and factors influencing achieving RVTCs ≤ 15% postoperatively.
EBMT China’s Voice | Team led by Yi Luo/Yibo Wu: Current Treatment Status and Prognosis of Acute Myeloid Leukemia with t(8;21) Chromosome Translocat

EBMT China’s Voice | Team led by Yi Luo/Yibo Wu: Current Treatment Status and Prognosis of Acute Myeloid Leukemia with t(8;21) Chromosome Translocat

Acute myeloid leukemia (AML) with t(8;21)(q22;q22.1) is one subtype among AML with recurrent genetic abnormalities, characterized by the translocation between chromosome 8q22 and chromosome 21q22. This translocation leads to the fusion of the RUNX1 gene on 8q22 with the RUNX1T1 gene on 21q22, forming the RUNX1-RUNX1T1 fusion gene. From April 14th to 17th, 2024, the 50th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held in Glasgow, UK. The conference focused on the latest advancements in stem cell transplantation and cell therapy, advancing towards better clinical outcomes for patients with hematologic diseases and blood tumors. In this congress, the team led by Yi Luo/Yibo Wu from The First Affiliated Hospital of Zhejiang University School of Medicine in China presented a clinical study, sharing the treatment status and prognosis of AML with t(8;21)(q22;q22.1). This journal is honored to invite Dr. Yibo Wu to share the research findings and their clinical significance with colleagues.
Professor Jun Guo Interprets the Updated CSCO Guidelines on Urothelial Carcinoma and Melanoma | 2024 CSCO Guideline Conference

Professor Jun Guo Interprets the Updated CSCO Guidelines on Urothelial Carcinoma and Melanoma | 2024 CSCO Guideline Conference

The 2024 CSCO Guideline Conference, co-hosted by the Chinese Society of Clinical Oncology (CSCO) and the Beijing Hope Science Clinical Oncology Research Foundation, took place in Jinan on April 26-27. At the event, Professor Jun Guo from Peking University Cancer Hospital was interviewed by "Oncology Frontier." He discussed significant updates in the new editions of the CSCO guidelines for urothelial carcinoma and melanoma, shared insights into the unique features of the CSCO guidelines, and provided an overview of the current and future states of anti-cancer drug development in China.
Professor Rui Ge: Review and Outlook on Advances in Breast Cancer Treatment | Northern Breast Cancer Salon Annual Review

Professor Rui Ge: Review and Outlook on Advances in Breast Cancer Treatment | Northern Breast Cancer Salon Annual Review

As time passes and seasons flow, we always embark on new journeys and endeavors through repeated reviews and outlooks. The annual review of the Northern Breast Cancer Salon and the discussion on the 2024 CSCO BC Guidelines update were held from January 5-6, 2024, in Beijing. "Oncology Frontier" specially interviewed Professor Rui Ge from East Hospital affiliated with Fudan University to reflect on the progress in breast cancer treatment i